← Leaderboards
Maria B Grant
University Of Alabama At Birmingham
$24,532,308
Attributed
$40,659,465
Total exposure
20
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,659,465 · 20
By mechanism
R01$37,054,291 · 15
RC1$1,978,180 · 2
R42$750,000 · 1
R21$725,000 · 1
R41$151,994 · 1
Top collaborators
- Michael Edwin Boulton31 shared
- Julia V Busik14 shared
- Charles J Frazier6 shared
- Irina A Pikuleva6 shared
- Steve F Abcouwer4 shared
- Qiuhong Li4 shared
- Susanne Mohr4 shared
- Mohan K. Raizada4 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Michael Edwin Boulton$9,864,814
- Louis B Nabors$6,698,272
- Natalia Filippova$501,049
Others in their field
Top investigators on “Diabetic Retinopathy”
- John M Lachin · George Washington University$140,240,809
- David M Nathan · Massachusetts Institute Of Technology$123,291,647
- Rose A Gubitosi-Klug · Case Western Reserve University$71,942,336
- Rohit Varma · University Of Southern California$56,244,772
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Adam R Glassman · Jaeb Center For Health Research, Inc.$50,075,374
Research focus
Diabetic RetinopathyDiabetes MellitusCellsRetinaDiabeticFunctional DisorderRepairedBlood VesselsBone MarrowEndothelial CellsPreventPathologyProteinsEquilibriumBlood CapillariesRetinalPathogenesisInflammatoryPhenotypeDiabetic MouseBaseMediatingIn VivoLead
Grant awards (99)
Endothelial Rap1 restricts inflammation in the retina$570,083
R01 · FY2025 · EY
RXR-based therapy for diabetic retinopathy$559,365
R01 · FY2025 · EY
Correction of diabetic retinopathy by mitochondrial transfer$554,407
R01 · FY2025 · EY
Brain-gut-retina axis in diabetic retinopathy$524,816
R01 · FY2025 · EY · contact PI
Anti-ceramide immunotherapy for diabetic retinopathy$422,886
R01 · FY2025 · EY
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2025 · EY · contact PI
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$320,663
R01 · FY2025 · EY · contact PI
Endothelial Rap1 restricts inflammation in the retina$603,488
R01 · FY2024 · EY
Correction of diabetic retinopathy by mitochondrial transfer$538,307
R01 · FY2024 · EY
Brain-gut-retina axis in diabetic retinopathy$532,390
R01 · FY2024 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$388,770
R01 · FY2024 · EY · contact PI
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$379,250
R01 · FY2024 · EY · contact PI
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2024 · EY · contact PI
RXR-based therapy for diabetic retinopathy$87,513
R01 · FY2024 · EY
Correction of diabetic retinopathy by mitochondrial transfer$571,182
R01 · FY2023 · EY
Brain-gut-retina axis in diabetic retinopathy$550,644
R01 · FY2023 · EY · contact PI
Hematopoietic cell mobilization from distinct bone marrow compartments following retinal injury$403,500
R01 · FY2023 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$388,770
R01 · FY2023 · EY · contact PI
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2023 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$377,107
R01 · FY2022 · EY · contact PI
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2022 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$50,490
R01 · FY2022 · EY · contact PI
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$535,787
R01 · FY2021 · EY · contact PI
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$391,180
R01 · FY2021 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$377,106
R01 · FY2021 · EY · contact PI
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$360,112
R01 · FY2021 · EY
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$554,358
R01 · FY2020 · EY · contact PI
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$461,792
R01 · FY2020 · EY · contact PI
Cholesterol homeostasis in pathogenesis of DR$413,020
R01 · FY2020 · EY · contact PI
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$403,279
R01 · FY2020 · EY · contact PI
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2020 · EY
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$552,358
R01 · FY2019 · EY · contact PI
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$471,105
R01 · FY2019 · EY · contact PI
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$403,279
R01 · FY2019 · EY · contact PI
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2019 · EY
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$552,358
R01 · FY2018 · EY · contact PI
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$522,331
R01 · FY2018 · EY · contact PI
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$474,726
R01 · FY2018 · EY · contact PI
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$415,404
R01 · FY2018 · EY · contact PI
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2018 · EY
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$555,127
R01 · FY2017 · EY · contact PI
OPTIMIZING SYSTEMIC STEM/PROGENITOR CELL THERAPY FOR AMD$546,187
R01 · FY2017 · EY
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$501,851
R01 · FY2017 · EY · contact PI
Human iPSC for repair of vasodegenerative vessels in diabetic retinopathy$445,991
R01 · FY2017 · EY · contact PI
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$125,000
R01 · FY2017 · EY · contact PI
LXR as a novel therapeutic target in diabetic retinopathy$532,879
R01 · FY2016 · EY · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$489,698
R01 · FY2016 · EY
LXR as a novel therapeutic target in diabetic retinopathy$582,429
R01 · FY2015 · EY · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$515,942
R01 · FY2015 · EY
Bone Marrow Neuropathy Drives Diabetic Retinopathy$452,377
R01 · FY2015 · EY · contact PI
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes$438,812
R01 · FY2015 · HL · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$513,987
R01 · FY2014 · EY
Bone Marrow Neuropathy Drives Diabetic Retinopathy$452,378
R01 · FY2014 · EY · contact PI
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes$436,585
R01 · FY2014 · HL · contact PI
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r$365,756
R01 · FY2014 · EY · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$589,587
R01 · FY2013 · EY
Bone Marrow Neuropathy Drives Diabetic Retinopathy$517,609
R01 · FY2013 · EY · contact PI
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes$424,113
R01 · FY2013 · HL · contact PI
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r$368,011
R01 · FY2013 · EY · contact PI
NO Dysregulation of the Peripheral Clock in Diabetic Complications$324,529
R01 · FY2013 · DK · contact PI
Bone marrow neuropathy drives diabetic retinopathy$519,583
R01 · FY2012 · EY · contact PI
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes$445,394
R01 · FY2012 · HL · contact PI
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r$347,437
R01 · FY2012 · EY · contact PI
NO Dysregulation of the Peripheral Clock in Diabetic Complications$299,608
R01 · FY2012 · DK · contact PI
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes$468,745
R01 · FY2011 · HL · contact PI
Circulating Progenitors determine angiogenic outcome in diabetic retinopathy$352,659
R01 · FY2011 · EY · contact PI
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r$347,437
R01 · FY2011 · EY · contact PI
NO Dysregulation of the Peripheral Clock in Diabetic Complications$299,824
R01 · FY2011 · DK · contact PI
A Cellular Approach to the Treatment of Diabetic Maculopathy$499,259
RC1 · FY2010 · EY
ACE2 as a target for pulmonary hypertension therapeutics$496,575
RC1 · FY2010 · HL
NO Dysregulation of the Peripheral Clock in Diabetic Complications$388,402
R01 · FY2010 · DK · contact PI
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r$362,479
R01 · FY2010 · EY · contact PI
Circulating Progenitors determine angiogenic outcome in diabetic retinopathy$360,112
R01 · FY2010 · EY · contact PI
Endothelial precursor dysfunction in development of diabetic acellular capillary$179,338
R01 · FY2010 · EY · contact PI
A Cellular Approach to the Treatment of Diabetic Maculopathy$496,925
RC1 · FY2009 · EY
ACE2 as a target for pulmonary hypertension therapeutics$485,421
RC1 · FY2009 · HL
Endothelial precursor dysfunction in development of diabetic acellular capillary$431,410
R01 · FY2009 · EY · contact PI
Circulating Progenitors determine angiogenic outcome in diabetic retinopathy$356,482
R01 · FY2009 · EY · contact PI
Endothelial precursor dysfunction in development of diabetic acellular capillary$410,650
R01 · FY2008 · EY · contact PI
Circulating Progenitors determine angiogenic outcome in diabetic retinopathy$341,648
R01 · FY2008 · EY · contact PI
Endothelial precursor dysfunction in development of diabetic acellular capillary$406,994
R01 · FY2007 · EY · contact PI
Circulating Progenitors determine angiogenic outcome in diabetic retinopathy$364,237
R01 · FY2007 · EY · contact PI
Carboxyamidotriazole for Neovascular Ocular Disease$151,994
R41 · FY2007 · EY · contact PI
Endothelial precursor dysfunction in development of diabetic acellular capillary$418,491
R01 · FY2006 · EY · contact PI
Targeting the IGF-1 System in Retinal Angiogenesis$319,682
R01 · FY2006 · EY · contact PI
Nonpeptide Somatostatin Agonists for Retinopathy$375,000
R42 · FY2005 · EY
INOS/REACTIVE OXYGEN SPECIES IN DIABETIC RETINOPATHY$363,750
R01 · FY2005 · EY
Targeting the IGF-1 System in Retinal Angiogenesis$327,375
R01 · FY2005 · EY
Nonpeptide Somatostatin Agonists for Retinopathy$375,000
R42 · FY2004 · EY
INOS/REACTIVE OXYGEN SPECIES IN DIABETIC RETINOPATHY$363,021
R01 · FY2004 · EY
Targeting the IGF-1 System in Retinal Angiogenesis$326,813
R01 · FY2004 · EY
INOS/REACTIVE OXYGEN SPECIES IN DIABETIC RETINOPATHY$362,500
R01 · FY2003 · EY
CXCR4/SDF-1 Axis in Proliferation Diabetic Retinopathy$362,500
R21 · FY2003 · EY
Targeting the IGF-1 System in Retinal Angiogenesis$326,250
R01 · FY2003 · EY
INOS/REACTIVE OXYGEN SPECIES IN DIABETIC RETINOPATHY$362,500
R01 · FY2002 · EY
CXCR4/SDF-1 Axis in Proliferation Diabetic Retinopathy$362,500
R21 · FY2002 · EY
ENDOTHELIAL CELL MATRIX INTERACTION/DIABETIC RETINOPATHY$216,812
R01 · FY2001 · EY
NITRIC OXIDE IN THE PATHOGENESIS OF DIABETIC RETINOPATHY$290,358
R01 · FY2000 · EY
ENDOTHELIAL CELL MATRIX INTERACTION/DIABETIC RETINOPATHY$212,152
R01 · FY2000 · EY